Jason C. Martin

Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults

R. Das, S. Halperin, B. Coller, 2019, The Journal of infectious diseases.

Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults

R. Das, S. Halperin, R. Rupp, 2017, The Journal of infectious diseases.

Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials

J. Cuzick, A. Giuliano, S. Kjaer, 2016, Pediatrics.

Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus–Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy

C. Rinaldo, P. Tebas, C. Benson, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA™).

S. Klopfer, Michelle G. Goveia, J. Stek, 2021, Vaccine.

Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.

S. Klopfer, J. Stek, P. Bhuyan, 2014, Vaccine.

Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.

K. Reisinger, J. Stek, F. Schödel, 2012, Vaccine.

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

Meihua Wang, M. Kohn, Temitope A Folaranmi, 2021, Human vaccines & immunotherapeutics.